Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Neuroblastoma | 105 | 2024 | 389 | 22.640 |
Why?
|
Infant | 63 | 2024 | 3105 | 2.440 |
Why?
|
Child, Preschool | 55 | 2024 | 3661 | 2.140 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 21 | 2024 | 2516 | 2.050 |
Why?
|
N-Myc Proto-Oncogene Protein | 20 | 2023 | 38 | 1.920 |
Why?
|
Anti-HIV Agents | 4 | 2021 | 155 | 1.770 |
Why?
|
Opsoclonus-Myoclonus Syndrome | 3 | 2020 | 4 | 1.750 |
Why?
|
Child | 61 | 2024 | 7065 | 1.730 |
Why?
|
HIV Infections | 10 | 2022 | 827 | 1.510 |
Why?
|
3-Iodobenzylguanidine | 8 | 2022 | 20 | 1.410 |
Why?
|
Cell Proliferation | 6 | 2024 | 1627 | 1.400 |
Why?
|
Prognosis | 35 | 2024 | 3729 | 1.370 |
Why?
|
Neoplasm Recurrence, Local | 11 | 2023 | 1347 | 1.290 |
Why?
|
Gene Amplification | 10 | 2021 | 133 | 1.280 |
Why?
|
Induction Chemotherapy | 5 | 2022 | 149 | 1.260 |
Why?
|
Disease-Free Survival | 24 | 2023 | 1210 | 1.200 |
Why?
|
Oncogene Proteins | 13 | 2015 | 61 | 1.130 |
Why?
|
Humans | 121 | 2024 | 87949 | 1.130 |
Why?
|
Biomarkers, Tumor | 7 | 2021 | 1511 | 1.080 |
Why?
|
Neoplasms, Second Primary | 6 | 2024 | 258 | 1.040 |
Why?
|
Neoplasm Staging | 24 | 2024 | 1967 | 1.030 |
Why?
|
Antineoplastic Agents | 14 | 2024 | 2392 | 1.010 |
Why?
|
Gene Expression Regulation, Neoplastic | 9 | 2024 | 1239 | 0.980 |
Why?
|
Central Nervous System Neoplasms | 2 | 2023 | 85 | 0.910 |
Why?
|
Pelvic Neoplasms | 3 | 2014 | 45 | 0.900 |
Why?
|
5-Methylcytosine | 3 | 2022 | 113 | 0.880 |
Why?
|
Antibodies, Monoclonal | 8 | 2021 | 1397 | 0.870 |
Why?
|
Methyltransferases | 1 | 2024 | 190 | 0.860 |
Why?
|
Cell-Free Nucleic Acids | 2 | 2023 | 81 | 0.850 |
Why?
|
Immunotherapy | 8 | 2021 | 655 | 0.830 |
Why?
|
Nuclear Proteins | 13 | 2015 | 721 | 0.830 |
Why?
|
Adolescent | 36 | 2024 | 9111 | 0.810 |
Why?
|
HIV-1 | 3 | 2021 | 164 | 0.800 |
Why?
|
Female | 62 | 2024 | 45399 | 0.790 |
Why?
|
Cell Differentiation | 5 | 2024 | 1501 | 0.780 |
Why?
|
Response Evaluation Criteria in Solid Tumors | 2 | 2020 | 56 | 0.770 |
Why?
|
Immunoglobulins, Intravenous | 2 | 2020 | 64 | 0.770 |
Why?
|
Survival Rate | 15 | 2024 | 1877 | 0.740 |
Why?
|
Electronic Health Records | 1 | 2024 | 339 | 0.730 |
Why?
|
Cell Line, Tumor | 13 | 2024 | 2513 | 0.730 |
Why?
|
Neoplasms, Muscle Tissue | 1 | 2020 | 12 | 0.730 |
Why?
|
Pharmaceutical Preparations | 1 | 2021 | 91 | 0.720 |
Why?
|
Hematopoietic Stem Cell Transplantation | 4 | 2022 | 883 | 0.710 |
Why?
|
DNA Methylation | 4 | 2022 | 650 | 0.700 |
Why?
|
Infant, Newborn | 15 | 2024 | 2436 | 0.700 |
Why?
|
Male | 51 | 2024 | 41697 | 0.690 |
Why?
|
Stem Cell Transplantation | 8 | 2019 | 187 | 0.680 |
Why?
|
Epigenomics | 1 | 2019 | 103 | 0.660 |
Why?
|
Naphthyridines | 1 | 2019 | 27 | 0.660 |
Why?
|
Chromosome Aberrations | 6 | 2020 | 389 | 0.650 |
Why?
|
Follow-Up Studies | 13 | 2024 | 3650 | 0.630 |
Why?
|
Decision Support Techniques | 1 | 2019 | 165 | 0.610 |
Why?
|
Oligonucleotide Array Sequence Analysis | 3 | 2016 | 696 | 0.600 |
Why?
|
Risk Factors | 20 | 2024 | 5405 | 0.590 |
Why?
|
Prednisone | 1 | 2017 | 258 | 0.580 |
Why?
|
Serum Albumin, Bovine | 1 | 2016 | 45 | 0.570 |
Why?
|
Palmitic Acid | 1 | 2016 | 27 | 0.570 |
Why?
|
Osteonectin | 1 | 2016 | 22 | 0.570 |
Why?
|
Neoadjuvant Therapy | 1 | 2019 | 354 | 0.550 |
Why?
|
Combined Modality Therapy | 9 | 2023 | 1703 | 0.550 |
Why?
|
Isotretinoin | 3 | 2021 | 23 | 0.540 |
Why?
|
Medical Oncology | 3 | 2021 | 374 | 0.540 |
Why?
|
Lipid Metabolism | 1 | 2016 | 198 | 0.520 |
Why?
|
Altruism | 1 | 2015 | 35 | 0.520 |
Why?
|
Anti-Inflammatory Agents | 1 | 2017 | 342 | 0.500 |
Why?
|
Interleukin-2 | 4 | 2022 | 250 | 0.490 |
Why?
|
Genetic Predisposition to Disease | 5 | 2017 | 2316 | 0.490 |
Why?
|
Adrenal Gland Neoplasms | 4 | 2017 | 82 | 0.470 |
Why?
|
Molecular Targeted Therapy | 1 | 2016 | 278 | 0.460 |
Why?
|
Genomics | 3 | 2021 | 740 | 0.450 |
Why?
|
Radiation Injuries | 1 | 2014 | 160 | 0.450 |
Why?
|
Risk Assessment | 11 | 2023 | 2274 | 0.430 |
Why?
|
Cohort Studies | 13 | 2021 | 2802 | 0.430 |
Why?
|
Salvage Therapy | 4 | 2021 | 235 | 0.430 |
Why?
|
Bone Marrow Neoplasms | 3 | 2020 | 18 | 0.430 |
Why?
|
Hypoxia | 2 | 2022 | 649 | 0.430 |
Why?
|
Pediatrics | 2 | 2021 | 350 | 0.420 |
Why?
|
Radiotherapy | 1 | 2014 | 331 | 0.420 |
Why?
|
Young Adult | 17 | 2024 | 6151 | 0.410 |
Why?
|
Cancer Survivors | 2 | 2024 | 92 | 0.400 |
Why?
|
L-Lactate Dehydrogenase | 3 | 2020 | 71 | 0.400 |
Why?
|
Microtubule-Associated Proteins | 1 | 2012 | 182 | 0.400 |
Why?
|
Drug Resistance, Neoplasm | 7 | 2021 | 610 | 0.400 |
Why?
|
Treatment Outcome | 14 | 2022 | 8104 | 0.400 |
Why?
|
Polymorphism, Single Nucleotide | 4 | 2017 | 2395 | 0.400 |
Why?
|
Benzenesulfonates | 1 | 2011 | 66 | 0.390 |
Why?
|
Limbic Encephalitis | 1 | 2011 | 11 | 0.390 |
Why?
|
Age Factors | 11 | 2021 | 1853 | 0.380 |
Why?
|
Algorithms | 1 | 2019 | 1857 | 0.380 |
Why?
|
MAP Kinase Signaling System | 1 | 2011 | 195 | 0.380 |
Why?
|
Kaplan-Meier Estimate | 9 | 2016 | 858 | 0.380 |
Why?
|
Prospective Studies | 11 | 2023 | 4247 | 0.380 |
Why?
|
Quinoxalines | 1 | 2011 | 50 | 0.370 |
Why?
|
Iodine Radioisotopes | 4 | 2022 | 134 | 0.370 |
Why?
|
Pyridines | 2 | 2012 | 313 | 0.370 |
Why?
|
Neoplasm Metastasis | 7 | 2019 | 1094 | 0.360 |
Why?
|
Parents | 3 | 2023 | 281 | 0.350 |
Why?
|
Palliative Care | 2 | 2023 | 263 | 0.350 |
Why?
|
Proportional Hazards Models | 8 | 2024 | 856 | 0.340 |
Why?
|
Recurrence | 5 | 2023 | 1168 | 0.340 |
Why?
|
Databases, Factual | 4 | 2024 | 839 | 0.340 |
Why?
|
Angiogenesis Inhibitors | 1 | 2011 | 313 | 0.340 |
Why?
|
International Cooperation | 3 | 2020 | 123 | 0.330 |
Why?
|
Biomedical Research | 3 | 2021 | 385 | 0.320 |
Why?
|
Protein Kinase Inhibitors | 2 | 2016 | 599 | 0.320 |
Why?
|
Health Status Disparities | 1 | 2010 | 175 | 0.320 |
Why?
|
Drug Administration Schedule | 2 | 2019 | 900 | 0.310 |
Why?
|
Adult | 23 | 2024 | 26131 | 0.300 |
Why?
|
Survivors | 3 | 2022 | 234 | 0.290 |
Why?
|
United States | 7 | 2024 | 6809 | 0.280 |
Why?
|
Ganglioneuroblastoma | 2 | 2018 | 4 | 0.270 |
Why?
|
Risk | 4 | 2019 | 660 | 0.260 |
Why?
|
Mice | 6 | 2024 | 11619 | 0.260 |
Why?
|
Gene Expression Profiling | 3 | 2016 | 1414 | 0.260 |
Why?
|
Proto-Oncogene Proteins | 2 | 2022 | 655 | 0.250 |
Why?
|
Granulocyte-Macrophage Colony-Stimulating Factor | 3 | 2022 | 112 | 0.250 |
Why?
|
Health Information Interoperability | 1 | 2024 | 2 | 0.240 |
Why?
|
Chromosomes, Human, Pair 11 | 3 | 2020 | 106 | 0.240 |
Why?
|
Mixed Function Oxygenases | 2 | 2022 | 68 | 0.240 |
Why?
|
Survival Analysis | 7 | 2021 | 1539 | 0.230 |
Why?
|
Gangliosides | 2 | 2016 | 10 | 0.230 |
Why?
|
Thoracic Neoplasms | 2 | 2014 | 64 | 0.230 |
Why?
|
Radionuclide Imaging | 3 | 2021 | 221 | 0.230 |
Why?
|
Genome-Wide Association Study | 3 | 2017 | 1659 | 0.230 |
Why?
|
Transplantation, Autologous | 2 | 2022 | 340 | 0.230 |
Why?
|
Receptor Protein-Tyrosine Kinases | 2 | 2016 | 156 | 0.230 |
Why?
|
Gene Frequency | 2 | 2017 | 682 | 0.220 |
Why?
|
Disease Progression | 5 | 2014 | 1479 | 0.220 |
Why?
|
Pregnancy Complications, Infectious | 3 | 2009 | 110 | 0.220 |
Why?
|
Incidence | 5 | 2024 | 1580 | 0.220 |
Why?
|
Radioimmunotherapy | 1 | 2023 | 27 | 0.220 |
Why?
|
Peripheral Blood Stem Cell Transplantation | 2 | 2013 | 64 | 0.220 |
Why?
|
Lymph Nodes | 2 | 2019 | 546 | 0.220 |
Why?
|
Watchful Waiting | 2 | 2013 | 61 | 0.210 |
Why?
|
Bone Neoplasms | 2 | 2017 | 331 | 0.210 |
Why?
|
Ferritins | 2 | 2020 | 29 | 0.210 |
Why?
|
Cell Hypoxia | 3 | 2022 | 170 | 0.210 |
Why?
|
Time Factors | 6 | 2019 | 5284 | 0.210 |
Why?
|
Chromosomes, Human, Pair 1 | 2 | 2020 | 100 | 0.210 |
Why?
|
Brain Neoplasms | 3 | 2014 | 773 | 0.210 |
Why?
|
Hypoxia-Inducible Factor 1 | 1 | 2022 | 42 | 0.210 |
Why?
|
Central Nervous System | 1 | 2023 | 152 | 0.200 |
Why?
|
Transcriptome | 2 | 2016 | 613 | 0.200 |
Why?
|
Adenosine | 1 | 2024 | 237 | 0.190 |
Why?
|
Neoplasm, Residual | 1 | 2022 | 172 | 0.190 |
Why?
|
Neoplasms | 3 | 2021 | 2984 | 0.190 |
Why?
|
Nomograms | 1 | 2020 | 29 | 0.190 |
Why?
|
Research Subjects | 1 | 2021 | 73 | 0.190 |
Why?
|
Retrospective Studies | 8 | 2023 | 8780 | 0.190 |
Why?
|
Genotype | 2 | 2017 | 1866 | 0.180 |
Why?
|
Research Report | 3 | 2021 | 43 | 0.180 |
Why?
|
Antineoplastic Agents, Immunological | 2 | 2019 | 190 | 0.180 |
Why?
|
Animals | 6 | 2024 | 27028 | 0.180 |
Why?
|
Rituximab | 1 | 2020 | 119 | 0.180 |
Why?
|
Attitude to Death | 1 | 2019 | 36 | 0.170 |
Why?
|
Myeloablative Agonists | 2 | 2016 | 36 | 0.170 |
Why?
|
Mitotic Index | 2 | 2020 | 20 | 0.170 |
Why?
|
Anti-Retroviral Agents | 1 | 2019 | 31 | 0.170 |
Why?
|
Drug Interactions | 1 | 2019 | 248 | 0.170 |
Why?
|
Cell Cycle | 2 | 2011 | 506 | 0.170 |
Why?
|
Cell Movement | 3 | 2022 | 780 | 0.170 |
Why?
|
Clinical Trials as Topic | 5 | 2020 | 1141 | 0.170 |
Why?
|
Ganglioneuroma | 1 | 2018 | 9 | 0.170 |
Why?
|
Clinical Trials, Phase III as Topic | 3 | 2017 | 172 | 0.170 |
Why?
|
Antiretroviral Therapy, Highly Active | 4 | 2009 | 74 | 0.170 |
Why?
|
Social Stigma | 1 | 2019 | 60 | 0.160 |
Why?
|
Adrenal Cortex Hormones | 1 | 2020 | 266 | 0.160 |
Why?
|
Mitosis | 2 | 2020 | 152 | 0.160 |
Why?
|
Heterografts | 1 | 2019 | 102 | 0.160 |
Why?
|
Antineoplastic Agents, Alkylating | 2 | 2016 | 138 | 0.160 |
Why?
|
Lymphoma | 1 | 2019 | 264 | 0.160 |
Why?
|
Receptors, KIR | 1 | 2017 | 9 | 0.150 |
Why?
|
Neoplasms, Complex and Mixed | 1 | 2017 | 7 | 0.150 |
Why?
|
Ataxia | 1 | 2017 | 39 | 0.150 |
Why?
|
Tumor Microenvironment | 1 | 2021 | 447 | 0.150 |
Why?
|
B7-H1 Antigen | 1 | 2019 | 267 | 0.150 |
Why?
|
Neurologic Examination | 1 | 2017 | 119 | 0.150 |
Why?
|
Pheochromocytoma | 1 | 2017 | 50 | 0.150 |
Why?
|
Nurse's Role | 1 | 2017 | 12 | 0.150 |
Why?
|
Age of Onset | 2 | 2015 | 311 | 0.150 |
Why?
|
Biomarkers | 3 | 2020 | 1744 | 0.140 |
Why?
|
Clinical Decision-Making | 1 | 2019 | 268 | 0.140 |
Why?
|
Databases, Nucleic Acid | 1 | 2016 | 41 | 0.140 |
Why?
|
Human Umbilical Vein Endothelial Cells | 1 | 2016 | 67 | 0.140 |
Why?
|
Patient Acceptance of Health Care | 1 | 2019 | 252 | 0.140 |
Why?
|
Neoplasm Proteins | 1 | 2020 | 539 | 0.140 |
Why?
|
Maintenance Chemotherapy | 1 | 2017 | 76 | 0.140 |
Why?
|
Buthionine Sulfoximine | 1 | 2016 | 7 | 0.140 |
Why?
|
Soft Tissue Neoplasms | 1 | 2017 | 129 | 0.140 |
Why?
|
Recovery of Function | 1 | 2017 | 287 | 0.140 |
Why?
|
Tissue Fixation | 1 | 2016 | 40 | 0.140 |
Why?
|
Mutation | 3 | 2016 | 4078 | 0.140 |
Why?
|
Paraffin Embedding | 1 | 2016 | 78 | 0.130 |
Why?
|
Formaldehyde | 1 | 2016 | 52 | 0.130 |
Why?
|
Melphalan | 1 | 2016 | 98 | 0.130 |
Why?
|
Multivariate Analysis | 3 | 2014 | 994 | 0.130 |
Why?
|
Predictive Value of Tests | 3 | 2015 | 1697 | 0.130 |
Why?
|
Medication Adherence | 1 | 2017 | 133 | 0.130 |
Why?
|
Thiamine | 1 | 2015 | 8 | 0.130 |
Why?
|
Wernicke Encephalopathy | 1 | 2015 | 6 | 0.130 |
Why?
|
Melanoma | 1 | 2019 | 462 | 0.130 |
Why?
|
Genes, myc | 1 | 2015 | 39 | 0.130 |
Why?
|
Autografts | 4 | 2017 | 28 | 0.130 |
Why?
|
Diffusion of Innovation | 1 | 2015 | 71 | 0.130 |
Why?
|
Lymphatic Metastasis | 2 | 2014 | 498 | 0.130 |
Why?
|
Positron-Emission Tomography | 1 | 2017 | 332 | 0.130 |
Why?
|
Apoptosis | 2 | 2019 | 1705 | 0.130 |
Why?
|
Hydroxamic Acids | 1 | 2015 | 50 | 0.130 |
Why?
|
In Situ Hybridization, Fluorescence | 2 | 2012 | 353 | 0.120 |
Why?
|
Immunosuppressive Agents | 1 | 2020 | 990 | 0.120 |
Why?
|
Genetic Association Studies | 2 | 2016 | 294 | 0.120 |
Why?
|
Peripheral Nervous System Neoplasms | 1 | 2014 | 19 | 0.120 |
Why?
|
Radiation-Sensitizing Agents | 1 | 2015 | 96 | 0.120 |
Why?
|
Interdisciplinary Communication | 1 | 2015 | 130 | 0.120 |
Why?
|
Antimetabolites, Antineoplastic | 1 | 2016 | 237 | 0.120 |
Why?
|
Karyotyping | 1 | 2014 | 253 | 0.120 |
Why?
|
DNA Copy Number Variations | 2 | 2012 | 175 | 0.120 |
Why?
|
Genetic Therapy | 1 | 2016 | 354 | 0.120 |
Why?
|
Cell Survival | 1 | 2016 | 977 | 0.120 |
Why?
|
Cooperative Behavior | 1 | 2015 | 179 | 0.120 |
Why?
|
Dacarbazine | 2 | 2013 | 102 | 0.120 |
Why?
|
Choice Behavior | 1 | 2015 | 160 | 0.120 |
Why?
|
Antibodies, Monoclonal, Humanized | 1 | 2019 | 951 | 0.120 |
Why?
|
Orbital Neoplasms | 1 | 2013 | 17 | 0.120 |
Why?
|
Patient Selection | 2 | 2015 | 685 | 0.120 |
Why?
|
Tubulin Modulators | 1 | 2013 | 24 | 0.120 |
Why?
|
SEER Program | 1 | 2014 | 196 | 0.120 |
Why?
|
Pyrazoles | 2 | 2012 | 148 | 0.120 |
Why?
|
Abdominal Neoplasms | 1 | 2013 | 39 | 0.120 |
Why?
|
Reproducibility of Results | 2 | 2018 | 2740 | 0.120 |
Why?
|
Immunomagnetic Separation | 1 | 2013 | 8 | 0.120 |
Why?
|
Camptothecin | 2 | 2013 | 190 | 0.120 |
Why?
|
Odds Ratio | 2 | 2012 | 682 | 0.120 |
Why?
|
Cell Nucleolus | 1 | 2013 | 24 | 0.110 |
Why?
|
Retroperitoneal Neoplasms | 1 | 2013 | 44 | 0.110 |
Why?
|
Image Interpretation, Computer-Assisted | 1 | 2018 | 681 | 0.110 |
Why?
|
Pyrimidines | 2 | 2018 | 370 | 0.110 |
Why?
|
Computational Biology | 1 | 2016 | 536 | 0.110 |
Why?
|
Mice, Nude | 2 | 2012 | 810 | 0.110 |
Why?
|
Renal Insufficiency | 1 | 2013 | 102 | 0.110 |
Why?
|
Cluster Analysis | 1 | 2014 | 369 | 0.110 |
Why?
|
Case-Control Studies | 1 | 2017 | 1843 | 0.110 |
Why?
|
Xenograft Model Antitumor Assays | 2 | 2012 | 467 | 0.110 |
Why?
|
Proto-Oncogene Proteins c-myc | 1 | 2013 | 126 | 0.110 |
Why?
|
DNA (Cytosine-5-)-Methyltransferases | 1 | 2012 | 60 | 0.100 |
Why?
|
Fenretinide | 1 | 2011 | 2 | 0.100 |
Why?
|
Topoisomerase I Inhibitors | 1 | 2011 | 34 | 0.100 |
Why?
|
Oncogene Proteins, Fusion | 1 | 2012 | 131 | 0.100 |
Why?
|
Severity of Illness Index | 1 | 2017 | 1827 | 0.100 |
Why?
|
Topotecan | 1 | 2011 | 45 | 0.100 |
Why?
|
Drug Monitoring | 3 | 2018 | 117 | 0.100 |
Why?
|
Multidrug Resistance-Associated Proteins | 1 | 2011 | 27 | 0.100 |
Why?
|
Niacinamide | 1 | 2011 | 114 | 0.100 |
Why?
|
Randomized Controlled Trials as Topic | 1 | 2015 | 834 | 0.100 |
Why?
|
Loss of Heterozygosity | 3 | 2018 | 86 | 0.100 |
Why?
|
Sulfonamides | 1 | 2013 | 317 | 0.100 |
Why?
|
Phenylurea Compounds | 1 | 2011 | 113 | 0.100 |
Why?
|
Neoplasm Transplantation | 1 | 2011 | 396 | 0.100 |
Why?
|
Radiopharmaceuticals | 3 | 2018 | 190 | 0.090 |
Why?
|
Renal Dialysis | 1 | 2013 | 335 | 0.090 |
Why?
|
Neoplasm Invasiveness | 1 | 2012 | 572 | 0.090 |
Why?
|
CD4 Lymphocyte Count | 3 | 2008 | 66 | 0.090 |
Why?
|
Transplantation Conditioning | 1 | 2013 | 372 | 0.090 |
Why?
|
Leukemia, Myeloid, Acute | 1 | 2016 | 779 | 0.090 |
Why?
|
Lymphoma, Non-Hodgkin | 1 | 2012 | 262 | 0.090 |
Why?
|
Fatal Outcome | 1 | 2011 | 295 | 0.090 |
Why?
|
Intention to Treat Analysis | 3 | 2019 | 69 | 0.090 |
Why?
|
Cyclophosphamide | 3 | 2018 | 300 | 0.090 |
Why?
|
Models, Biological | 1 | 2016 | 1759 | 0.090 |
Why?
|
Pregnancy Rate | 1 | 2009 | 20 | 0.090 |
Why?
|
Neovascularization, Pathologic | 1 | 2011 | 364 | 0.080 |
Why?
|
Immunohistochemistry | 3 | 2021 | 1786 | 0.080 |
Why?
|
DNA-Binding Proteins | 1 | 2014 | 1224 | 0.080 |
Why?
|
Protease Inhibitors | 1 | 2007 | 72 | 0.070 |
Why?
|
DNA, Mitochondrial | 1 | 2008 | 186 | 0.070 |
Why?
|
Head and Neck Neoplasms | 1 | 2014 | 1057 | 0.070 |
Why?
|
Mitochondrial Proteins | 1 | 2008 | 126 | 0.070 |
Why?
|
Leukocytes, Mononuclear | 1 | 2008 | 202 | 0.070 |
Why?
|
Communication | 2 | 2020 | 448 | 0.070 |
Why?
|
Consensus | 2 | 2018 | 349 | 0.070 |
Why?
|
Neoplasm Grading | 2 | 2020 | 366 | 0.070 |
Why?
|
Etoposide | 2 | 2018 | 197 | 0.060 |
Why?
|
Doxorubicin | 2 | 2018 | 297 | 0.060 |
Why?
|
Carboplatin | 2 | 2018 | 302 | 0.060 |
Why?
|
Viral Load | 2 | 2019 | 152 | 0.060 |
Why?
|
Surveys and Questionnaires | 2 | 2023 | 2574 | 0.060 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 1 | 2012 | 1100 | 0.060 |
Why?
|
Longitudinal Studies | 2 | 2023 | 1037 | 0.060 |
Why?
|
Goals | 1 | 2023 | 64 | 0.060 |
Why?
|
Treatment Failure | 2 | 2014 | 288 | 0.060 |
Why?
|
Capsules | 2 | 2013 | 38 | 0.050 |
Why?
|
Morbidity | 1 | 2022 | 147 | 0.050 |
Why?
|
Vincristine | 1 | 2021 | 112 | 0.050 |
Why?
|
RNA, Small Interfering | 2 | 2014 | 555 | 0.050 |
Why?
|
Diploidy | 1 | 2020 | 31 | 0.050 |
Why?
|
Up-Regulation | 2 | 2014 | 726 | 0.040 |
Why?
|
Therapies, Investigational | 1 | 2019 | 17 | 0.040 |
Why?
|
Lung Neoplasms | 1 | 2012 | 2321 | 0.040 |
Why?
|
Antiviral Agents | 1 | 2003 | 513 | 0.040 |
Why?
|
Alabama | 1 | 2019 | 11 | 0.040 |
Why?
|
Consolidation Chemotherapy | 1 | 2019 | 23 | 0.040 |
Why?
|
Decision Making | 2 | 2019 | 655 | 0.040 |
Why?
|
Pilot Projects | 2 | 2013 | 861 | 0.040 |
Why?
|
Epigenesis, Genetic | 2 | 2014 | 495 | 0.040 |
Why?
|
Hepatomegaly | 1 | 2018 | 15 | 0.040 |
Why?
|
Filgrastim | 1 | 2018 | 57 | 0.040 |
Why?
|
Recombinant Proteins | 1 | 2021 | 1020 | 0.040 |
Why?
|
Azepines | 1 | 2018 | 23 | 0.040 |
Why?
|
Research Design | 1 | 2022 | 593 | 0.040 |
Why?
|
Quality of Life | 2 | 2019 | 1638 | 0.040 |
Why?
|
Retreatment | 1 | 2018 | 108 | 0.040 |
Why?
|
Ecosystem | 1 | 2021 | 336 | 0.040 |
Why?
|
Blotting, Western | 2 | 2011 | 794 | 0.040 |
Why?
|
Receptors, KIR3DL1 | 1 | 2017 | 1 | 0.040 |
Why?
|
Receptors, KIR2DL1 | 1 | 2017 | 3 | 0.040 |
Why?
|
Polymerase Chain Reaction | 2 | 2011 | 927 | 0.040 |
Why?
|
Comparative Genomic Hybridization | 1 | 2016 | 39 | 0.040 |
Why?
|
Thymus Hyperplasia | 1 | 2016 | 3 | 0.040 |
Why?
|
Motivation | 1 | 2019 | 294 | 0.040 |
Why?
|
Pregnancy | 3 | 2009 | 2974 | 0.040 |
Why?
|
Glutamate-Cysteine Ligase | 1 | 2016 | 7 | 0.030 |
Why?
|
Microsatellite Repeats | 1 | 2016 | 148 | 0.030 |
Why?
|
Fluorodeoxyglucose F18 | 1 | 2017 | 139 | 0.030 |
Why?
|
Ligands | 1 | 2017 | 437 | 0.030 |
Why?
|
Glutathione | 1 | 2016 | 108 | 0.030 |
Why?
|
Emotions | 1 | 2019 | 348 | 0.030 |
Why?
|
Drug Synergism | 1 | 2016 | 303 | 0.030 |
Why?
|
Cost of Illness | 1 | 2016 | 147 | 0.030 |
Why?
|
Norepinephrine Plasma Membrane Transport Proteins | 1 | 2015 | 5 | 0.030 |
Why?
|
Tomography, X-Ray Computed | 2 | 2018 | 2624 | 0.030 |
Why?
|
Models, Statistical | 1 | 2018 | 575 | 0.030 |
Why?
|
Acetylation | 1 | 2015 | 126 | 0.030 |
Why?
|
RNA, Viral | 2 | 2008 | 333 | 0.030 |
Why?
|
Chicago | 1 | 2019 | 1397 | 0.030 |
Why?
|
DNA Repair | 1 | 2016 | 359 | 0.030 |
Why?
|
Cyclohexylamines | 1 | 2014 | 7 | 0.030 |
Why?
|
Suspensions | 1 | 2013 | 6 | 0.030 |
Why?
|
Physician-Patient Relations | 1 | 2019 | 617 | 0.030 |
Why?
|
Response Elements | 1 | 2014 | 63 | 0.030 |
Why?
|
Middle Aged | 3 | 2019 | 25477 | 0.030 |
Why?
|
Hematopoietic Stem Cells | 1 | 2016 | 297 | 0.030 |
Why?
|
International Agencies | 1 | 2013 | 34 | 0.030 |
Why?
|
Quality Control | 1 | 2014 | 116 | 0.030 |
Why?
|
Chi-Square Distribution | 1 | 2014 | 360 | 0.030 |
Why?
|
Hematologic Diseases | 1 | 2013 | 78 | 0.030 |
Why?
|
Cytosine | 1 | 2014 | 128 | 0.030 |
Why?
|
Immunoenzyme Techniques | 1 | 2013 | 306 | 0.030 |
Why?
|
Magnetic Resonance Imaging | 2 | 2018 | 3425 | 0.030 |
Why?
|
Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2014 | 154 | 0.030 |
Why?
|
Real-Time Polymerase Chain Reaction | 1 | 2014 | 281 | 0.030 |
Why?
|
Histones | 1 | 2015 | 322 | 0.030 |
Why?
|
Nervous System Diseases | 1 | 2013 | 157 | 0.030 |
Why?
|
Adrenalectomy | 1 | 2012 | 46 | 0.030 |
Why?
|
Chromosomes, Human, Pair 17 | 1 | 2012 | 110 | 0.030 |
Why?
|
Virus Diseases | 1 | 2013 | 96 | 0.030 |
Why?
|
Gastrointestinal Diseases | 1 | 2013 | 147 | 0.030 |
Why?
|
Gene Deletion | 1 | 2013 | 341 | 0.030 |
Why?
|
Ploidies | 1 | 2011 | 41 | 0.030 |
Why?
|
Skin | 1 | 2015 | 570 | 0.030 |
Why?
|
Tretinoin | 1 | 2012 | 127 | 0.030 |
Why?
|
Thymopentin | 1 | 2011 | 2 | 0.030 |
Why?
|
Drug Resistance, Multiple | 1 | 2011 | 20 | 0.030 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2016 | 1939 | 0.020 |
Why?
|
Translocation, Genetic | 1 | 2012 | 266 | 0.020 |
Why?
|
Isoenzymes | 1 | 2012 | 272 | 0.020 |
Why?
|
Research | 1 | 2012 | 250 | 0.020 |
Why?
|
Antibodies | 1 | 2013 | 353 | 0.020 |
Why?
|
RNA, Messenger | 1 | 2016 | 1996 | 0.020 |
Why?
|
Receptors, Interleukin-2 | 1 | 2010 | 66 | 0.020 |
Why?
|
Gene Silencing | 1 | 2011 | 175 | 0.020 |
Why?
|
Australia | 1 | 2010 | 102 | 0.020 |
Why?
|
Logistic Models | 1 | 2014 | 1200 | 0.020 |
Why?
|
Biopsy | 1 | 2014 | 1181 | 0.020 |
Why?
|
Lymphocyte Count | 1 | 2010 | 96 | 0.020 |
Why?
|
Chemotherapy, Adjuvant | 1 | 2012 | 475 | 0.020 |
Why?
|
Age Distribution | 1 | 2010 | 200 | 0.020 |
Why?
|
North America | 1 | 2010 | 184 | 0.020 |
Why?
|
Japan | 1 | 2010 | 303 | 0.020 |
Why?
|
Aged | 2 | 2019 | 18750 | 0.020 |
Why?
|
Europe | 1 | 2010 | 313 | 0.020 |
Why?
|
Administration, Oral | 1 | 2011 | 680 | 0.020 |
Why?
|
Liver Neoplasms | 1 | 2016 | 761 | 0.020 |
Why?
|
Down-Regulation | 1 | 2011 | 513 | 0.020 |
Why?
|
Gravidity | 1 | 2009 | 7 | 0.020 |
Why?
|
Transfection | 1 | 2011 | 907 | 0.020 |
Why?
|
Sex Education | 1 | 2009 | 10 | 0.020 |
Why?
|
Infectious Disease Transmission, Vertical | 1 | 2009 | 48 | 0.020 |
Why?
|
Congenital Abnormalities | 1 | 2009 | 63 | 0.020 |
Why?
|
Contraceptive Agents, Female | 1 | 2009 | 31 | 0.020 |
Why?
|
Aged, 80 and over | 1 | 2019 | 6655 | 0.020 |
Why?
|
Drug Therapy, Combination | 1 | 2010 | 795 | 0.020 |
Why?
|
Cytochromes c | 1 | 2008 | 27 | 0.020 |
Why?
|
Birth Weight | 1 | 2008 | 145 | 0.020 |
Why?
|
Body Height | 1 | 2008 | 100 | 0.020 |
Why?
|
Mice, Transgenic | 1 | 2011 | 1563 | 0.020 |
Why?
|
Infant, Low Birth Weight | 1 | 2007 | 57 | 0.020 |
Why?
|
Phenotype | 1 | 2014 | 2424 | 0.020 |
Why?
|
Lactic Acid | 1 | 2007 | 92 | 0.020 |
Why?
|
Models, Genetic | 1 | 2012 | 941 | 0.020 |
Why?
|
Genetic Variation | 1 | 2014 | 1366 | 0.020 |
Why?
|
Diagnostic Imaging | 1 | 2011 | 476 | 0.020 |
Why?
|
Triglycerides | 1 | 2007 | 231 | 0.020 |
Why?
|
Cholesterol, HDL | 1 | 2007 | 165 | 0.020 |
Why?
|
Pregnancy Outcome | 1 | 2007 | 252 | 0.020 |
Why?
|
Health Knowledge, Attitudes, Practice | 1 | 2009 | 520 | 0.020 |
Why?
|
Disease Models, Animal | 1 | 2011 | 2317 | 0.010 |
Why?
|
Hepatitis A Vaccines | 1 | 2003 | 3 | 0.010 |
Why?
|
Hepatitis A Antibodies | 1 | 2003 | 3 | 0.010 |
Why?
|
Mumps virus | 1 | 2003 | 3 | 0.010 |
Why?
|
Tetanus Toxoid | 1 | 2003 | 10 | 0.010 |
Why?
|
Mycobacterium avium-intracellulare Infection | 1 | 2003 | 5 | 0.010 |
Why?
|
Azithromycin | 1 | 2003 | 13 | 0.010 |
Why?
|
Antibodies, Bacterial | 1 | 2003 | 99 | 0.010 |
Why?
|
Acquired Immunodeficiency Syndrome | 1 | 2003 | 80 | 0.010 |
Why?
|
Signal Transduction | 1 | 2012 | 3331 | 0.010 |
Why?
|
Anti-Bacterial Agents | 1 | 2003 | 765 | 0.010 |
Why?
|